Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical experiences with pepleomycin].

H Furue, T Komita, H Mugitani

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |May 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Seasonal and interannual variations in feeding station behavior of cattle: effects of sward and meteorological conditions.

    Animal : an international journal of animal bioscience·2014
    Same author

    Processing of CD109 by furin and its role in the regulation of TGF-beta signaling.

    Oncogene·2010
    Same author

    Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro.

    Neuroscience·2009
    Same author

    Action of neuropeptide Y on nociceptive transmission in substantia gelatinosa of the adult rat spinal dorsal horn.

    Neuroscience·2005
    Same author

    [Anti-nociceptive effect of calcitonin on chronic pain associated with osteoporosis].

    Clinical calcium·2005
    Same author

    Functional reorganization of the spinal pain pathways in developmental and pathological conditions.

    Novartis Foundation symposium·2004
    Same journal

    [A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Recent Advances in the Treatment of HER2-Altered Solid Tumors].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [BRAF-Mutant Solid Tumor].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    See all related articles

    Peplomycin showed similar efficacy and side effects to bleomycin in cancer patients. However, peplomycin offered longer remission durations and improved survival, suggesting potential advantages in cancer treatment.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Peplomycin, a derivative of bleomycin, was hypothesized to possess enhanced anti-tumor activity and reduced pulmonary toxicity.
    • Conventional treatments had proven ineffective for the selected patient cohort.

    Purpose of the Study:

    • To evaluate the efficacy and safety of peplomycin in patients with malignant lymphoma and squamous cell carcinoma.
    • To compare the outcomes of peplomycin treatment with historical data from bleomycin treatment.

    Main Methods:

    • An intermittent dosage regimen of peplomycin (10 mg twice weekly) was administered.
    • Patients included those with malignant lymphoma or squamous cell carcinoma who had not responded to prior therapies.
    • Treatment outcomes, including response rates, side effects, remission duration, and survival, were recorded and analyzed.

    Related Experiment Videos

    Main Results:

    • Objective responses were observed in malignant lymphoma (2 complete responses, 5 partial responses) and squamous cell carcinoma (2 partial responses).
    • Common adverse events included fever (38.5%) and pulmonary complications (19.2%).
    • Peplomycin demonstrated response rates and side effect profiles comparable to bleomycin, but with significantly longer remission durations and survival.

    Conclusions:

    • Peplomycin exhibits comparable anti-cancer efficacy and toxicity to bleomycin.
    • Peplomycin may offer improved long-term outcomes, including extended remission and survival, compared to bleomycin.
    • Further investigation into peplomycin's therapeutic potential in specific cancer types is warranted.